8-K: Calidi Biotherapeutics Board Changes Announced
Current Report (8-K)
Calidi Biotherapeutics announced changes to its Board of Directors, including the departure of Allan J. Camaisa and the appointment of Scott Leftwich to the Audit Committee.
Summary
- Allan J. Camaisa will not seek re-election to the Board of Directors, with his term expiring at the 2026 annual stockholder meeting.
- The Board size will be reduced from six to five directors following Mr. Camaisa's departure.
- Scott Leftwich has been appointed as a member of the Audit Committee, effective immediately.
- These changes were made following Mr. Camaisa's notification and were recommended by the Nominating and Corporate Governance Committee.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting routine corporate governance updates without significant financial or strategic implications.
Positives
- The departure of Allan J. Camaisa is not due to any disagreement with the Company, indicating a smooth transition.
- The appointment of Scott Leftwich to the Audit Committee strengthens the committee's expertise.
Negatives
- A reduction in the size of the Board of Directors may indicate a consolidation of oversight or a strategic shift.
Risks
- Potential impact on board dynamics and decision-making with a reduced board size.
- Any perceived instability or change in leadership direction due to director departures.
Future Outlook
The filing does not contain specific forward-looking financial guidance. The primary outlook relates to the upcoming 2026 annual stockholder meeting and the resulting board composition.
Management Comments
- Mr. Camaisa's decision to allow his Director term to expire did not result from any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Industry Context
StockSavvy.ai notes that board composition changes are common in the biotechnology sector, often reflecting strategic shifts, governance enhancements, or the natural lifecycle of director tenures. The reduction in board size can sometimes signal a move towards greater efficiency or a more focused strategic direction.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Allan J. Camaisa | Date of 2026 annual stockholder meeting | Intent to allow term to expire | |
| Member of the Audit Committee | Scott Leftwich | April 1, 2026 | Appointment by the Board on recommendation of the Nominating and Corporate Governance Committee |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Size Reduction | The size of the Board of Directors was reduced from six to five members. | Effective on the date of the 2026 annual stockholder meeting | May lead to more streamlined decision-making but potentially less diverse perspectives. |
| Committee Appointment | Scott Leftwich was appointed to the Audit Committee. | April 1, 2026 | Enhances the expertise and capacity of the Audit Committee. |
Stakeholder Impact
- Shareholders: The change in board composition may influence future strategic decisions and corporate governance oversight.
- Employees: No direct impact mentioned, but board changes can indirectly affect company direction and stability.
- Creditors: No direct impact mentioned, as the changes are governance-related and not financial distress signals.
Next Steps
- The Company's 2026 annual stockholder meeting will occur, at which time Mr. Camaisa's director term will expire.
- The Board of Directors will operate with five members following the 2026 annual stockholder meeting.
Key Dates
| Date | Description |
|---|---|
| 2026-03-29 | Date of earliest event reported (Allan J. Camaisa informed Nominating and Corporate Governance Committee of his intent to allow term to expire). |
| 2026-04-01 | Board appointed Scott Leftwich to the Audit Committee and reduced the size of the Board. |
| 2026-04-02 | Date of the filing. |
| 2026-XX-XX | Date of the Company's 2026 annual stockholder meeting (expected date for Mr. Camaisa's term expiration). |
Keywords
Calidi Biotherapeutics, Board of Directors, Audit Committee, Director Departure, Corporate Governance, Stockholder Meeting, SEC Filing, 8-K
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.